Guangwen Zhang1, Jinsong Zhang1, Ziliang Xu1, Xiaocheng Wei2, and Jialiang Ren3
1Department of Radiology, Xijing Hospital, Xi’an, China, 2Department of MR Research, GE Healthcare China,, Beijing, China, 3Department of Pharmaceuticals Diagnostics, GE Healthcare China, Beijing, China
Synopsis
Keywords: Cancer, Diffusion/other diffusion imaging techniques
The
prognosis prediction of locally advanced rectal
cancer (LARC) was important to
individualized treatment, we investigated the
performance of
ultra-high b-value DWI (UHBV-DWI) in progression risk
prediction of LARC and compare with routine DWI. It was found that ADCuh derived
from UHBV-DWI performed better than ADC based on routine DWI in predicting
prognosis of LARC. The model based on combination of ADCuh, TNM-stage and extramural
venous invasion (EMVI) could help to indicate progression risk before
treatment.
Introduction
It is crucial to
make a precise prediction about the progression risk with the aim of individualized
treatment. Analysis of routine DWI involving prognosis prediction have been investigated
recently in rectal cancer [1-3] and colorectal
cancer [4, 5].
However, routine DWI has not performed satisfactorily and has exhibited
controversial results in prognosis prediction of rectal cancer [6].
Recently, ultra-high
b-value DWI (UHBV-DWI) is increasingly explored in relation to the cerebral
system [7-9] and prostate cancer [10, 11] and has showed considerable potential in tumor
grading and detection. Thus, in this study, UHBV-DWI was introduced to evaluate
the progression risk of locally advanced rectal cancer (LARC) and compare
with routine DWI. Methods
Patients
The institutional
review board of Xijing hospital approved this retrospective study. Patients (n
= 230) were consecutively recruited from November 2016 to May 2019 according to
the inclusive criteria. The outcomes in this study were 3-year progression free
survival (PFS). The date of last follow-up was June 30, 2021.
Multi-b value DWI acquisition
All patients underwent
traditional DWI (b = 0, 1000 s/mm2) and multi-b-value DWI (b = 0~3500
s/mm2) on a 3.0 T MR scanner (Discovery MR750, GE Medical Systems)
with a single-shot SE-EPI diffusion-weighted sequence. Other parameters of multi-b-value
DWI were as follows: TR/TE = 4607/78.8 ms, FOV = 430×320 mm2, Matrix
= 128×128, Slice thickness = 5 mm, Intersection gap = 0.5 mm and NEX = 4 to 8
(increasing with b-values).
ADC, ADCuh calculation and survival assessment
Routine DWI (b = 0,
1000s/mm2) was used to calculate ADC with VOI drawn at b1000 DWI and
UHBV-DWI (b = 0, 1700~3500 s/mm2) was used to generate ADCuh with VOI
drawn at b1700 DWI with mono-exponential model. Mean value of ADC and ADCuh
were record for further analysis.
The performance of
ADC and ADCuh in predicting prognosis was explored with time-dependent receiver
operator characteristic curve (ROC) and Kaplan-Meier curves. Univariate and
multivariate COX proportional hazard regression model was used to perform survival analysis and
construct prognostic models for 3-year PFS prediction
with clinicopathologic factor and functional parameter of DWI. The
time-dependent ROC, decision curve analysis (DCA) and calibration curve was
used to evaluate the discrimination, net benefit and agreement of prognostic
models respectively.
Statistics
Statistical analyses
were carried out with R software (version 4.1.2), and two-side P <
0.05 was considered statistically significant for all tests. Results
Patient characteristics
A total of 112 patients with TNM-stage Ⅱ-Ⅲ
were finally involved for analysis according to exclusion criteria. The median
follow-up time was 41 (range: 2-55) months. The 3-year PFS of the whole cohort
was 76%.
Survival analysis with ADC and ADCuh
By using the time
dependent ROC analysis, the optimal cutoff values of ADC and ADCuh were 1.140´10-3 mm2/s
and 0.716´10-3 mm2/s according to patients
3-year PFS. The Kaplan-Meier curves exhibited significant difference between
the low ADC group and high ADC group in 3-year PFS (83% vs 56%, P = 0.001, Figure 1a) as same as ADCuh (92%
vs 62%, P < 0.001, Figure 1b).
Time-dependent ROC showed that ADCuh was superior to ADC in 3-year PFS
assessment (AUC = 0.754 vs 0.586, P < 0.001, Figure 2a). MR images of patients
with proregression and without progression during follow-up was shown in Figure
3.
Prognostic model construction
Univariate and multivariate COX analysis found that EMVI, ADC and ADCuh were the
independent factors for 3-year PFS (Figure 4). We constructed
three prognostic models for 3-year PFS assessment, model 1 (TNM +EMVI), model 2
(TNM+EMVI+ADC) and model 3 (TNM+EMVI+ADCuh). The model 3 has better performance
than model 1 and model 2 (AUC = 0.805, 0.719, 0.688, respectively, Figure 2b). Decision
curve (Figure 2c) exhibited that patients might have higher net benefit than
model 1 and model 2. Meanwhile, calibration curves (Figure 2d-f) showed better agreement of
model 3 between predicted PFS and observed PFS than other two models.
Discussion
This study found the ADCuh derived from
UHBV-DWI performed better than ADC derived from routine DWI for 3-year PFS assessment
in LARC (AUC = 0.754 vs 0.586) and combined
model (TNM+EMVI+ADCuh) has good discrimination,
net benefit and agreement for 3-year PFS prediction
(AUC = 0.805).
Though previous studies have demonstrated
ADC was correlated with local recurrence or distance metastasis [1, 3] and
disease-free survival [3],
we found the performance of ADC was inferior to ADCuh in assessing PFS. Theoretically,
when signal attenuation arrives at ultra-high b-value region, the sensitivity
to smaller spatial scale enhances and enables DWI to explore tissue
microstructure on complexity and heterogeneity more powerfully than routine DWI
[12].
In fact, previous studies have showed that UHBV-DWI performed better than traditional DWI in tumor grading [8] and detection [10].
The combined
model we constructed with ADCuh needs to be investigated and validated in
additional datasets and future randomized controlled trials. Conclusions
ADCuh based on UHBV-DWI
is an independent prognosis factor for 3-year PFS of LARC and performed better
than ADC from routine DWI. The combined model (ADCuh+TNM-stage+EMVI) could be a promising
tool for progression risk prediction.Acknowledgements
We thank Prof. Lei
Shang for suggestions about statistical analyses.References
1. Moon SJ, Cho SH, Kim GC, Kim WH, Kim
HJ, Shin KM, Lee SM, Park JS, Choi GS, Kim SH: Complementary value of pre-treatment apparent diffusion coefficient in
rectal cancer for predicting tumor recurrence. Abdominal radiology 2016, 41(7):1237-1244.
2. Bakke
KM, Hole KH, Dueland S, Groholt KK, Flatmark K, Ree AH, Seierstad T, Redalen
KR: Diffusion-weighted magnetic
resonance imaging of rectal cancer: tumour volume and perfusion fraction
predict chemoradiotherapy response and survival. Acta oncologica 2017, 56(6):813-818.
3. Noda
Y, Goshima S, Kajita K, Kawada H, Kawai N, Koyasu H, Matsuo M, Bae KT: Prognostic Value of Diffusion MR Imaging
and Clinical-Pathologic Factors in Patients with Rectal Cancer. Iran J Radiol 2018, 15(1):e57080.
4. Alis
D, Durmaz ESM, Gulsen F, Bas A, Kabasakal L, Sager S, Numan F: Prognostic value of ADC measurements in
predicting overall survival in patients undergoing (90)Y radioembolization for
colorectal cancer liver metastases. Clinical
imaging 2019, 57:124-130.
5. Takahashi
Y, Hayano K, Ohira G, Imanishi S, Hanaoka T, Watanabe H, Hirata A, Kawasaki Y,
Miyauchi H, Matsubara H: Histogram
Analysis of Diffusion-Weighted MR Imaging as a Biomarker to Predict Survival of
Surgically Treated Colorectal Cancer Patients. Digestive diseases and sciences 2021, 66(4):1227-1232.
6. Schurink
NW, Lambregts DMJ, Beets-Tan RGH: Diffusion-weighted
imaging in rectal cancer: current applications and future perspectives. The British journal of radiology 2019, 92(1096):20180655.
7. Xueying
L, Zhongping Z, Zhoushe Z, Li G, Yongjin T, Changzheng S, Zhifeng Z, Peihao C,
Hao X, Li H: Investigation of Apparent
Diffusion Coefficient from Ultra-high b-Values in Parkinson's Disease. European radiology 2015, 25(9):2593-2600.
8. Tan
Y, Zhang H, Wang XC, Qin JB, Wang L: The
value of multi ultra high-b-value DWI in grading cerebral astrocytomas and its
association with aquaporin-4. The
British journal of radiology 2018, 91(1086):20170696.
9. Bai
Y, Liu T, Chen L, Gao H, Wei W, Zhang G, Wang L, Kong L, Liu S, Liu H et al: Study of Diffusion Weighted Imaging Derived Diffusion Parameters as
Biomarkers for the Microenvironment in Gliomas. Frontiers in oncology 2021, 11:672265.
10. Cha
SY, Kim E, Park SY: Why Is a b-value
Range of 1500-2000 s/mm(2) Optimal for Evaluating Prostatic Index Lesions on
Synthetic Diffusion-Weighted Imaging? Korean
journal of radiology 2021, 22(6):922-930.
11. Woo
S, Suh CH, Kim SY, Cho JY, Kim SH: Head-To-Head
Comparison Between High- and Standard-b-Value DWI for Detecting Prostate
Cancer: A Systematic Review and Meta-Analysis. AJR American journal of roentgenology 2018, 210(1):91-100.
12. Tang
L, Zhou XJ: Diffusion MRI of cancer:
From low to high b-values. Journal of
magnetic resonance imaging : JMRI 2019, 49(1):23-40.